As telehealth continues to shape the future of health care, providers must stay informed about evolving regulations, particularly those governing the remote prescribing of controlled substances. This webinar will provide an overview of the current and upcoming DEA telehealth flexibilities for prescribing Schedule II-V controlled substances, including a specific policy for prescribing buprenorphine to treat opioid use disorder that goes into effect March 21. Attendees will gain a clear understanding of when these rules go into effect, when they expire, and how they impact telehealth practice.
Join us for this timely discussion with Lydia Kotowski as we break down key policy updates and what they mean for telehealth providers.
DEA Telehealth Flexibilities for Prescribing Controlled Substances: What Practitioners Need to Know
March
20,
2025
Event Description
Presenter
Lydia Kotowski
Policy Analyst, OCHIN.
Lydia Kotowski is a member of the External Affairs team at OCHIN where she works as a policy analyst. She earned her Juris Doctorate and Master of Healthcare Administration from The Ohio State University. She has worked for numerous health care organizations, including a hospital, policy nonprofit, care navigation company, and a medical-legal partnership. She has developed a special focus on federal laws and regulations and compliance.
